GICS Sector : Healthcare
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine.The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits.It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Singular Genomics Announces Closing of Acquisition by Deerfield Management
Feb -21
Investors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities Fraud
Jan -30
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
Jan -29
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
Jan -28
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Jan -27
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Jan -26
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Jan -25
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Jan -24
Singular Genomics Systems' Proprietary Sequencing Solutions growth is driven by increasing adoption in precision medicine, genomics research, and diagnostics. The company's unique sequencing technology offers higher accuracy, faster turnaround times, and lower costs, attracting customers seeking improved genomic analysis. Additionally, strategic partnerships, expanding product offerings, and growing demand for personalized medicine contribute to the 14.37% growth.
A highly automated, high-throughput sequencing instrument designed for genomic analysis
A high-throughput, automated sequencing instrument for targeted sequencing applications
A comprehensive software suite for data analysis and interpretation of genomic data
A range of reagents and consumables designed for use with Singular Genomics' instruments
The threat of substitutes for Singular Genomics Systems, Inc. is medium due to the presence of alternative genetic sequencing technologies, but the company's proprietary sequencing technology provides a competitive advantage.
The bargaining power of customers is low due to the specialized nature of genetic sequencing services, which limits the ability of customers to negotiate prices or switch to alternative providers.
The bargaining power of suppliers is medium due to the presence of multiple suppliers of genetic sequencing reagents and equipment, but the company's dependence on these suppliers for critical components limits its negotiating power.
The threat of new entrants is high due to the growing demand for genetic sequencing services and the potential for new companies to enter the market with innovative technologies or business models.
The intensity of rivalry is high due to the competitive nature of the genetic sequencing market, with multiple established players and new entrants vying for market share.
| Value | |
|---|---|
| Debt Weight | 29.61% |
| Debt Cost | 3.95% |
| Equity Weight | 70.39% |
| Equity Cost | 11.08% |
| WACC | 8.97% |
| Leverage | 42.06% |
Value: 6.4
Growth: 3.4
Quality: 4.8
Yield: 0.0
Momentum: 9.5
Volatility: 2.7
1-Year Total Return ->
Value: 7.8
Growth: 3.2
Quality: 3.4
Yield: 0.0
Momentum: 8.0
Volatility: 3.3
1-Year Total Return ->
Value: 9.6
Growth: 2.8
Quality: 4.8
Yield: 0.0
Momentum: 0.5
Volatility: 2.0
1-Year Total Return ->
Value: 6.0
Growth: 2.8
Quality: 3.1
Yield: 0.0
Momentum: 4.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.6
Growth: 3.2
Quality: 4.3
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 9.2
Growth: 1.1
Quality: 2.6
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->